First-Dose and Steady-State Profile Displays

Why Separate First-Dose and Steady-State Profiles?

A concentration measured after the first dose can look quite different from a concentration measured at the same time after a repeated-dose regimen. With repeated dosing, drug from earlier doses may still be present when the next dose is given. A display that places the observations side by side can make this accumulation visible, but only if the timing and regimen are made clear. Otherwise, a higher profile might reflect a different dose, a different sampling schedule, or other differences between the observations—not accumulation alone.

The key plotting decision is to align concentration measurements by time since the relevant dose, not by study day or visit label. The figure should also identify which observations are after the first dose and which are after repeated dosing at steady state. The introductory material on concentration-time plots and dose-normalized concentration-time plots supplies the basic display conventions; here the emphasis is on comparing these two dosing conditions without presuming that they are otherwise alike.

Definition: A first-dose profile describes concentrations at specified times after an initial dose, with the prior dosing history stated. A steady-state profile describes concentrations over a dosing interval after repeated administration has produced a recurring concentration-time pattern under a specified regimen. A comparison is time-aligned when the profiles are indexed by time since dose and the compared observations correspond to the same or clearly identified post-dose times.

“Steady state” is a property of the dosing history and concentration pattern, not simply a label for a later visit. It should be supported by the study schedule or an appropriate assessment. A measurement from a later visit is not automatically a steady-state observation, and a first-dose sample is not necessarily free of prior drug if the participant had previous treatment or an insufficient washout. Plot labels should describe the actual dosing history rather than imply one that has not been verified.

What an Idealized Accumulation Pattern Looks Like

A simple model gives a useful reference for interpreting displays. Suppose an intravenous bolus dose \(D\) is given every \(\tau\) time units, the apparent volume of distribution is \(V\), and concentrations decline by first-order elimination with rate constant \(k>0\). Assume linear pharmacokinetics, the same dose and interval on every occasion, no drug present before the first dose, and enough repeated doses to reach steady state. For this illustration, there is no absorption phase: each bolus produces an immediate concentration increment \(D/V\).

For time \(t\) after a dose, where \(0\leq t<\tau\), the first-dose concentration is the contribution from that dose alone. At steady state, the concentration includes the current dose and residual contributions from earlier doses. Index those earlier doses by \(j\), with \(j=0\) denoting the current dose and \(j=1,2,\ldots\) denoting doses given one, two, and more intervals earlier.

C_1(t)=\frac{D}{V}e^{-kt}, \qquad C_{\mathrm{ss}}(t)=\sum_{j=0}^{\infty}\frac{D}{V}e^{-k(t+j\tau)}.

The ratio at a matched post-dose time follows by factoring the current-dose contribution out of the sum. The index \(j\) denotes dose number; \(k\) remains the elimination rate constant throughout.

\frac{C_{\mathrm{ss}}(t)}{C_1(t)} = \frac{\sum_{j=0}^{\infty}(D/V)e^{-k(t+j\tau)}}{(D/V)e^{-kt}} = \sum_{j=0}^{\infty}e^{-kj\tau} = \frac{1}{1-e^{-k\tau}}, \qquad k>0.

The final equality is the geometric-series result: its first term is 1 and its common ratio is \(e^{-k\tau}\), which lies between 0 and 1 when \(k>0\) and \(\tau>0\). Under these assumptions, the ratio is greater than 1 and does not depend on \(t\). Thus the model predicts a steady-state profile that is a constant multiple of the first-dose profile at every matched time. This is a model-based reference, not a rule that real displayed profiles must be parallel or have a constant ratio.

Worked Example: Calculating an Idealized Accumulation Ratio

Consider a hypothetical drug with an elimination half-life of 8 hours, given by identical intravenous bolus doses every 12 hours. For the model above, calculate the expected steady-state-to-first-dose concentration ratio at a matched post-dose time.

The elimination rate constant is \(k=\ln(2)/t_{1/2}\). With \(t_{1/2}=8\) hours, \(k=0.6931/8=0.08664\) per hour. The dose interval is \(\tau=12\) hours, so \(k\tau=0.08664\times12=1.0397\).

R=\frac{1}{1-e^{-k\tau}} =\frac{1}{1-e^{-(0.08664)(12)}} =\frac{1}{1-0.3536} =1.547.

Under the stated assumptions, the steady-state concentration is about 1.547 times the first-dose concentration at the same time after dosing. The result applies to this idealized regimen and model. It is not a universal expected ratio for observed profiles, particularly when absorption, nonlinear pharmacokinetics, regimen changes, or differing participant characteristics matter.

Designing a Clear Comparison

A useful display makes the comparison conditions visible. Start with the dose-relative time axis and show the interval from dose to the next scheduled dose when that interval defines the steady-state profile. Label the first-dose and steady-state observations directly, including dose, route, formulation, and interval when relevant. If the two conditions differ in any of these features, state the difference in the figure or its caption rather than relying on the reader to infer comparability.

For observations from the same participant under a documented unchanged regimen, an overlay or a paired panel can show how that person’s profile changes. For multiple participants, thin individual traces can reveal whether an apparent population-level pattern is shared or driven by a few profiles; summary curves can be added when they do not conceal the underlying data. The earlier material on within- and between-subject variation is relevant to that choice. When profiles are from different participants or otherwise unpaired, use separate panels or clearly differentiated traces and avoid implying a within-person change.

Use only the time range supported by the observations. Connecting sparse observations with lines can suggest concentrations were measured continuously, so make the line convention clear and avoid extending curves beyond observed times without an explicit model. If sampling times differ between conditions, show the actual points and the sampling coverage. A missing point at a particular time is not evidence that concentrations there were equal, lower, or higher.

Worked Example: Reading Matched Profiles for One Participant

Suppose a hypothetical participant received the same dose and formulation at the same 12-hour interval on both occasions. The first-dose and steady-state samples were collected at matched times. The concentrations below are illustrative measurements, in mg/L.

Time after dose (hours)	First dose (mg/L)	Steady state (mg/L)
1	18	28
4	13	20
8	8	12
12	5	7

Plot time after dose on the horizontal axis and concentration on the vertical axis, using distinct symbols or colors for the two conditions. At each matched time, the steady-state value is higher. For example, at 4 hours the difference is \(20-13=7\) mg/L, and the steady-state-to-first-dose ratio is \(20/13=1.538\). At 8 hours, the ratio is \(12/8=1.500\).

The data show a higher observed steady-state profile for this participant under the stated matched conditions. The ratios are not identical across the displayed times, unlike the constant ratio predicted by the simple bolus model. These few measurements do not establish why they differ or whether the discrepancy is meaningful; measurement variation, profile shape, and departures from model assumptions are possible explanations. The plot supports a descriptive comparison, not a causal claim or a definitive model check.

When the Profiles Are Not Directly Comparable

A side-by-side plot remains useful when conditions differ, but its interpretation must be narrower. A concentration is tied to dose history and time. A comparison at different times after dose mixes the potential effect of accumulation with the concentration’s change over the interval. A comparison at equal times after dose can still be confounded by a different dose or regimen. Dose-normalized displays, introduced in the earlier material on dose-normalized concentration-time plots, can help describe some dose differences, but they do not by themselves make unlike regimens or participants exchangeable.

Worked Example: Why Unequal Sampling Times Do Not Establish Accumulation

In a hypothetical data set, first-dose concentrations are 14 mg/L at 2 hours and 7 mg/L at 8 hours. Steady-state concentrations are 30 mg/L at 1 hour and 15 mg/L at 6 hours. The maintenance dose is also 150 mg, while the first dose was 100 mg. A tempting calculation is \(30/14=2.143\), followed by the claim that steady state produced a 2.143-fold increase.

That ratio compares a steady-state sample at 1 hour with a first-dose sample at 2 hours. The samples are not time-matched, and the doses differ. The calculation \(30/14=2.143\) is arithmetically correct, but it is not an interpretable estimate of an accumulation ratio. The 15/7 comparison is also invalid for the same reasons: it pairs 6 hours with 8 hours and compares different doses.

A defensible display would show the actual sampling times, distinguish the dose conditions, and state that the regimens differ. If the scientific question requires a matched comparison, the data need suitably aligned sampling under comparable conditions or a justified model-based analysis. Neither visual proximity nor dose normalization alone repairs unequal post-dose times.

Diagnostics, Alternatives, and Limitations

Before interpreting a display, check the records that define the plotted conditions: dose date and time, sample time, dose amount, interval, route, formulation, and prior dosing history. Confirm that the plotted time is genuinely time since dose and that the steady-state designation is supported. A mislabeled dose time can shift an entire profile, while residual concentrations before a nominal first dose can make the “first-dose” curve include prior drug.

Look for warning signs in the display itself: poor overlap in sampling times, one condition represented by many more observations, an apparent discontinuity at the next-dose boundary, or a trend that changes when a few participants are removed. If values below quantification limits occur, show or describe them according to the analysis convention rather than silently treating them as zero. These checks help identify when the visual contrast is driven by data structure rather than a stable pharmacokinetic pattern.

An overlay emphasizes direct shape comparison but can become crowded. Separate panels preserve the same axes while reducing overlap. Paired lines or panels are appropriate only when observations can genuinely be paired by participant; unpaired groups should not be drawn as if each first-dose profile belongs to a particular steady-state profile. Time-binned summaries can make a large data set easier to scan, but differing bin coverage and sample counts should be visible. No one display establishes comparability: the design and dosing history determine what the comparison can support.

The idealized derivation has important limits. Oral or other extravascular dosing introduces absorption; nonlinear elimination can invalidate superposition; changing dose intervals or missed doses alter the contributions from prior doses; and the simple ratio need not hold for an observed profile. Even with linear pharmacokinetics, differences among participants or between study conditions can produce profiles that do not follow a single theoretical curve. The plot is therefore an exploratory description that can motivate questions, not a substitute for checking the design and assumptions.

Common pitfall: “The steady-state points are higher, so repeated dosing caused the entire difference.” This reasoning ignores whether dose, time after dose, participant, and prior treatment history were comparable. The correction is to describe the observed contrast first, verify the conditions, and attribute it to accumulation only when the dosing history and comparison support that interpretation.

Key takeaway: Align profiles by time since dose, state the regimen and dosing history, and distinguish a visual pattern consistent with accumulation from a controlled or model-based conclusion. The idealized accumulation ratio is a reference under specific assumptions, not a universal property of plotted data.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions.

In the repeated-dose bolus model, what does the summation index \(j\) represent, and why must it be distinct from the elimination rate constant \(k\)?
A first-dose sample is collected 3 hours after dose and a steady-state sample 7 hours after dose. Can their concentration ratio be interpreted directly as an accumulation ratio? Why or why not?
Under the idealized model, suppose \(e^{-k\tau}=0.25\). What is the steady-state-to-first-dose ratio at a matched post-dose time?
What additional information is needed before interpreting a higher steady-state profile as a pattern consistent with accumulation?

Solutions. (1) \(j\) indexes how many dosing intervals earlier a contributing dose was administered; \(k\) is the fixed elimination rate constant. Distinct symbols prevent confusing a changing summation index with a model parameter. (2) No. The observations are at different post-dose times, so concentration change over the interval is mixed with the dosing-condition difference; align the times or use an appropriately justified analysis. (3) \(R=1/(1-0.25)=1/0.75=1.333\), so the model predicts a ratio of 1.333 under its assumptions. (4) Check dose and interval, route and formulation, participant pairing, prior dosing or washout, sample-time alignment, and evidence that steady state was reached. A higher profile is descriptive until those conditions support an accumulation interpretation.